Guardian Pharmacy Services, Inc. GRDN
As ofNov 20, 2026, 2:56 PM EST
- YTD
- +56.25%
- 1 year
- +70.10%
5D -2.49 (-5.02%)
- Market cap
- 2.98B
- Revenue (ttm)
- 1.46B
- Profit margin
- 5.13%
- EPS (ttm)
- 1.17
- Shares out
- 63.32M
- P/E ratio
- 40.26
- Forward P/E
- 31.08
- YTD return
- +56.25%
- 1-year return
- +70.10%
- 50-day average
- 42.91
- Volume
- 259.31K
- Avg volume
- 545.36K
- Open
- 47.38
- Previous close
- 46.67
- Day's range
- 46.82 – 47.45
- 52-week range
- 26.34 – 50.85
- Beta
- 0.06
- Analysts
- Strong Buy
- Price target
- 51.29 (+9.1%)
- Earnings date
- Mar 10, 2027
Key statistics
- 200-day average
- 39.13
- Enterprise value
- 3.03B
- Price / sales
- 2.03
- Price / book
- 11.06
- Revenue growth
- -1.70%
- Free cash flow
- 75.56M
- Total cash
- 119.66M
- Total debt
- 40.60M
- Return on equity
- 32.01%
- Short % of float
- 4.35%
Fundamental scorecard
12 of 25 checks passed on GRDN’s reported financials
12of 25 checks passed
- Value 0 of 5
- Growth 3 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 49.00
- Target (mean)
- 51.29
- Target (high)
- 55.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 10, 2027
Expected Mar 10, 2027. Consensus EPS estimate 0.45429.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 10, 2027 | Dec 30, 2026 | 0.45 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.3146 | 0.33 | +0.02 | +4.90% |
| Aug 6, 2026 | Jun 30, 2026 | 0.2617 | 0.29 | +0.03 | +10.81% |
| May 6, 2026 | Mar 31, 2026 | 0.24 | 0.29 | +0.05 | +20.83% |
| Mar 11, 2026 | Dec 31, 2025 | 0.27 | 0.37 | +0.10 | +37.04% |
| Nov 10, 2025 | Sep 30, 2025 | 0.24 | 0.25 | +0.01 | +4.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Keybanc | init | — | Overweight |
| Sep 21, 2026 | Truist Securities | main | Buy | Buy |
| Aug 7, 2026 | Oppenheimer | main | Outperform | Outperform |
| Jun 17, 2026 | Truist Securities | main | Buy | Buy |
| Jun 17, 2026 | B of A Securities | main | Buy | Buy |
| May 7, 2026 | Oppenheimer | main | Outperform | Outperform |
About Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- guardianpharmacy.com
News
Guardian Pharmacy Services, Inc. (GRDN) Hits Fresh High: Is There Still Room to Run?
Guardian Pharmacy Services, Inc. to Participate in Upcoming Citi Annual Global Healthcare Conference
Guardian Pharmacy Service Q3 2026 Earnings Call Transcript Guardian Pharmacy Service Raises FY2026 Sales Guidance from $1.430B-$1.450B to $1.440B-$1.460B vs $1.442B Est
Your note
Sign in to keep a note on GRDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMAN JOHN | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 24, 2026 | 0 |
| BINDLEY CAPITAL PARTNERS I, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 24, 2026 | 16,669,700 |
| BINDLEY WILLIAM E | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 24, 2026 | 0 |
| BURKE FRED | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 24, 2026 | 3,438,060 |
| CARDINAL EQUITY FUND L P | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 24, 2026 | 1,287,240 |
| FORBES KENDALL | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 24, 2026 | 1,651,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 5.22% | 3,303,843 | 154.16M | Sep 29, 2026 |
| Blackrock Inc. | 3.82% | 2,418,789 | 112.86M | Sep 29, 2026 |
| Wellington Management Group, LLP | 3.51% | 2,221,497 | 103.66M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 2.28% | 1,446,706 | 67.50M | Sep 29, 2026 |
| Woodline Partners LP | 2.06% | 1,306,340 | 60.95M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 1.84% | 1,167,891 | 54.49M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.62% | 1,028,313 | 47.98M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.30% | 820,410 | 38.28M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 0.90% | 570,825 | 26.63M | Aug 30, 2026 |
| Putnam Funds Trust-PUTNAM CORE EQUITY FUND | 0.80% | 508,135 | 23.71M | Jul 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 0.75% | 476,800 | 22.25M | Aug 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund | 0.74% | 470,706 | 21.96M | Jun 29, 2026 |
